Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

*This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*

Shanghai INT Medical Instruments Co., Ltd.*

上海瑛泰醫療器械股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1501)

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Joint Placing Agents

CICC 中金公司

兴证国际 INDUSTRIAL SECURITIES INTERNATIONAL

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

On 14 January 2026 (after trading hours), the Company entered into the Placing Agreement with the Joint Placing Agents, pursuant to which the Joint Placing Agents have conditionally agreed, as the Company's joint placing agents, to procure, on a best effort basis, the Placee(s) (who and whose ultimate beneficial owner(s) (where applicable) will be Independent Third Parties) to purchase 35,200,000 Placing Shares at the Placing Price of HK$26.00 per Placing Share.

Assuming that there will be no change in the number of issued Shares between the date of this announcement and the Closing Date, the number of 35,200,000 Placing Shares under the Placing represents (i) approximately 33.78% of the number of existing issued H Shares and 20.00% of number of existing issued Shares as at the date of the announcement; and (ii) approximately 25.25% of the number of issued H Shares and approximately 16.67% of the number of issued Shares as enlarged by the allotment and issue of the Placing Shares.

It is expected that the Joint Placing Agents will procure not less than six (6) Placees, who will be professional, institutional, corporate or other investors, to subscribe for the Placing Shares. The Placees of the Placing Shares shall be determined by the Joint Placing Agents subject to the requirements of the Listing Rules and each of the Placees and its ultimate beneficial owners shall be Independent Third Parties. It is expected that none of the Placees will become a substantial shareholder of the Company immediately after the Closing.

The Placing Price of HK$26.00 per Placing Share represents: (a) a discount of approximately 16.13% to the closing price of HK$31.00 per Share as quoted on the Stock Exchange on 14 January 2026, being the Last Trading Day; and (b) a discount of approximately 15.56% to the average closing price of HK$30.792 per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including 13 January 2026, being the last trading day immediately prior to the date on which the Placing Price is fixed.

Assuming all the Placing Shares are fully placed and subject to the Closing, it is expected that the maximum gross proceeds and net proceeds (after deducting the Placing commission and other relevant costs and expenses of the Placing) from the Placing will be approximately HK$915.20 million and HK$884.31 million, respectively, representing a net issue price of HK$25.12 per Placing Share. The Company intends to allocate the net proceeds of the Placing in the manner detailed in the paragraph headed "REASONS FOR AND BENEFITS OF THE PLACING AND USE OF PROCEEDS" in this announcement.

No Shareholders' approval is required for the Placing and the allotment and issue of the Placing Shares by the Company, as the Placing Shares will be allotted and issued pursuant to the General Mandate granted to the Board by a resolution of the Shareholders passed at the EGM held on 29 August 2025, under which the Board may allot, issue and deal with new Shares not exceeding 35,200,000 new Shares (representing approximately 20% of the issued Shares as at the date of the passing of the resolution at the EGM and excluding treasury Shares). As at the date of this announcement and immediately prior to the entering into of the Placing Agreement, the Company has not issued any Shares under the General Mandate.

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Placing Shares on the Stock Exchange.

As the Placing is on a best effort basis, and the Closing is subject to the Placing Agreement not being terminated, and the satisfaction (or waiver) of a number of conditions under the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the Shares.

On 14 January 2026 (after trading hours), the Company entered into the Placing Agreement with the Joint Placing Agents, pursuant to which the Joint Placing Agents have conditionally agreed, as the Company's joint placing agents, to procure, on a best effort basis, the Placee(s) (who and whose ultimate beneficial owner(s) (where applicable) will be Independent Third Parties) to purchase 35,200,000 Placing Shares at the Placing Price of HK$26.00 per Placing Share.

The principal terms of the Placing Agreement are set out below:

THE PLACING AGREEMENT

Date

14 January 2026 (after trading hours)

Parties to the Placing Agreement

(1) The Company

(2) China International Capital Corporation Hong Kong Securities Limited, as the Joint Placing Agent

(3) China Industrial Securities International Capital Limited, as the Joint Placing Agent

The Joint Placing Agents

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the Joint Placing Agents is an Independent Third Party.

Information on the Placees

It is expected that the Joint Placing Agents will procure not less than six (6) Placees, who will be professional, institutional, corporate or other investors, to subscribe for the Placing Shares. The Placees of the Placing Shares shall be determined by the Joint Placing Agents subject to the requirements of the Listing Rules and each of the Placees and its ultimate beneficial owners shall be Independent Third Parties. It is expected that none of the Placees will become a substantial shareholder of the Company immediately after the Closing.

Number of Placing Shares

Assuming that there will be no change in the number of issued Shares between the date of this announcement and the Closing Date, the number of 35,200,000 Placing Shares under the Placing represents (i) approximately 33.78% of the number of existing issued H Shares and 20.00% of number of existing issued Shares as at the date of this announcement; and (ii) approximately 25.25% of the number of issued H Shares and approximately 16.67% of the number of issued Shares as enlarged by the allotment and issue of the Placing Shares. The aggregate nominal value of the Placing Shares to be allotted and issued will be RMB35,200,000.

Placing Price

The Placing Price of HK$26.00 per Placing Share represents: (a) a discount of approximately 16.13% to the closing price of HK$31.00 per Share as quoted on the Stock Exchange on 14 January 2026, being the Last Trading Day; and (b) a discount of approximately 15.56% to the average closing price of HK$30.792 per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including 13 January 2026, being the last trading day immediately prior to the date on which the Placing Price is fixed.

The Placing Price was determined with reference to the market conditions and the prevailing market price of the Shares and was negotiated on an arm's length basis between the Company and the Joint Placing Agents. The Directors consider that the Placing Price and the terms and conditions of the Placing Agreement are fair and reasonable and are in the interests of the Company and the Shareholders as a whole.

The Placing Price is exclusive of applicable brokerage, trading fees, transaction fees and levies.

Conditions of the Placing

The obligations of the Joint Placing Agents under the Placing Agreement are subject to certain conditions ("**Conditions**"), including:

(a) the Listing Committee of the Stock Exchange granting approval for the listing of and permission to deal in the Placing Shares and such listing and permission not subsequently being revoked prior to the Closing;

(b) all necessary approvals and clearances from all relevant PRC regulatory authorities in connection with the Placing having been obtained to the reasonable satisfaction of the Joint Placing Agents, such approvals and clearances not materially conflicting with or altering the terms of the Placing Agreement and not imposing any material adverse conditions on any party of the Placing Agreement;

(c) the representations and warranties made by the Company pursuant to the Placing Agreement being true and accurate and not misleading as of the date of the Placing Agreement and the Closing Date;

(d) there not having been certain customary events as set out in the Placing Agreement that would make the placement of the Placing Shares impractical or inadvisable, or would materially prejudice trading of the Placing Shares in the secondary market; and

(e) the Company having complied with all of the agreements and undertakings and satisfied all of the conditions on its part to be complied with or satisfied under the Placing Agreement on or before the Closing Date.

The Company shall use its reasonable endeavours to procure the fulfilment of the Conditions on or before the Closing Date.

RANKING OF THE PLACING SHARES

The Placing Shares will rank, upon allotment and issue, *pari passu* in all respects with each other, among themselves and with the other Shares in issue on the date of allotment and issue of the Placing Shares.

GENERAL MANDATE TO ALLOT AND ISSUE THE PLACING SHARES

No Shareholders' approval is required for the Placing and the allotment and issue of the Placing Shares by the Company, as the Placing Shares will be allotted and issued pursuant to the General Mandate granted to the Board by a resolution of the Shareholders passed at the EGM held on 29 August 2025, under which the Board may allot, issue and deal with new Shares not exceeding 35,200,000 new Shares (representing approximately 20% of the issued Shares as at the date of the passing of the resolution at the EGM).

As at the date of this announcement and immediately prior to the entering into of the Placing Agreement, the Company has not issued any Shares under the General Mandate.

APPLICATION FOR LISTING OF THE PLACING SHARES

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Placing Shares on the Stock Exchange.

The Placing is conditional upon, among other things, the Stock Exchange granting the listing of, and permission to deal in, the Placing Shares.

CSRC FILINGS

The Company shall complete the CSRC Filings in connection with the Placing.

REASONS FOR AND BENEFITS OF THE PLACING AND USE OF PROCEEDS

The Company is a leading Chinese vascular interventional device manufacturer as well as one of the few medical device groups that cover the entire industry chain from design and development of mould and equipment, product injection, product assembly, product packaging to sterilization in the PRC.

The Placing is intended to support the Company's ongoing and stable business development needs, further strengthening the Company's core competitive capabilities and ensuring sustainable growth.

The Directors believe that the Placing will be conducive to strengthening the Group's liquidity and financial position, broadening the Shareholder base, optimizing the capital structure of the Company and supporting the healthy and sustainable development of the Company.

Assuming all the Placing Shares are fully placed and subject to the Closing, it is expected that the maximum gross proceeds and net proceeds (after deducting the Placing commission and other relevant costs and expenses of the Placing) from the Placing will be approximately HK$915.20 million and HK$884.31 million, respectively, representing a net issue price of HK$25.12 per Placing Share. Such net proceeds are currently intended to be applied as follows: (a) approximately 56.54% or HK$500.00 million for funding the Company's continued expansion of product portfolios through investment and potential acquisition in the medical devices industry; (b) approximately 23.75% or HK$210.00 million for repayment of existing interest-bearing bank borrowings; and (c) approximately 19.71% or HK$174.31 million for the Company's working capital and other general corporate purposes including staff costs and day-to-day operational expenses. The net proceeds from the Placing are expected to be fully utilized by 2027. Such expected time frame is based on the Board's best assessment, and is subject to adjustment depending on the Company's future development, market conditions and prevailing business circumstances. As at the date of this announcement, the Group has not identified any specific target for investment and acquisition in the medical devices industry.

In view of the above, the Directors consider that the terms of the Placing Agreement and the transactions contemplated thereunder (including the Placing and the Placing Price) are fair and reasonable and with reference to the prevailing market conditions. The Placing and the entry into of the Placing Agreement are in the interest of the Company and the Shareholders as a whole.

EFFECTS OF THE PLACING ON SHAREHOLDING STRUCTURE OF THE COMPANY

As at the date of this announcement, the total number of issued Shares is 176,000,000 Shares, comprising 104,213,392 H Shares and 71,786,608 Domestic Shares.

The table below sets out a summary of the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately upon the Closing (assuming there is no change in the number of issued Shares up to the Closing Date):

Shareholders	**As at the date of this announcement**		**Immediately upon the Closing (assuming there is no change in the number of issued Shares up to the Closing Date)**	
	Number of issued Shares	*Approximate percentage in the total number of issued Shares[1] (%)*	*Number of issued Shares*	*Approximate percentage in the total number of issued Shares[1] (%)*
Domestic Shares				
Core connected persons[2]	51,643,748	29.34	51,643,748	24.45
Other Domestic Shareholders	20,142,860	11.44	20,142,860	9.54
Total number of Domestic Shares	**71,786,608**	**40.79**	**71,786,608**	**33.99**
H Shares				
Core connected persons[3]	74,195,592	42.16	74,195,592	35.13
The Placees	—	—	35,200,000	16.67
Other H Shareholders	30,017,800	17.06	30,017,800	14.21
Total number of H Shares	**104,213,392**	**59.21**	**139,413,392**	**66.01**
Total number of Shares	**176,000,000**	**100.00**	**211,200,000**	**100.00**

Note:

(1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.

(2) Including (i) 36,228,570 Domestic Shares controlled by our Directors, Dr. Liang Dongke (梁棟科), Dr. Song Yuan (宋媛), Mr. Lin Sen (林森) and Mr. Wang Ruiqin (王瑞琴), and (ii) 15,415,178 Domestic Shares controlled by our substantial Shareholders, Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership) (寧波懷格泰益股權投資合夥企業(有限合夥)), Ningbo Huaige Gongxin Equity Investment Partnership (Limited Partnership) (寧波懷格共信股權投資合夥企業(有限合夥)), Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)), Mr. Wang Kai (王鍇) and Ms. Zhao Wei (趙威), collectively 51,643,748 Domestic Shares.

(3) Including the H Shares controlled by our substantial Shareholders: (i) 42,857,142 H Shares controlled by Shanghai Kindly Enterprise Development Group Co., Ltd. (上海康德萊企業發展集團股份有限公司), Shanghai Kindly Holding Group Co., Ltd. (上海康德萊控股集團有限公司), Kindly Holding Co., Ltd. (康德萊控股有限公司), Shanghai Gongye Investment Co., Ltd. (上海共業投資有限公司), Mr. Zhang Xianmiao (張憲淼), Ms. Zheng Aiping (鄭愛平) and Mr. Zhang Wei (張偉), (ii) 12,494,250 H Shares controlled by Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership) (寧波懷格泰益股權投資合夥企業(有限合夥)), Ningbo Huaige Gongxin Equity Investment Partnership (Limited Partnership) (寧波懷格共信股權投資合夥企業(有限合夥)), Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)), Mr. Wang Kai (王鍇) and Ms. Zhao Wei (趙威), and (iii) 18,844,200 H Shares controlled by Central Huijin Investment Ltd., China Orient Asset Management (International) Holding Limited, China Orient International Fund Management Limited, China Orient Multi-Strategy Master Fund and China Orient Enhanced Income Fund, collectively controlling 74,195,592 H Shares.

EQUITY FUND RAISING ACTIVITY OF THE COMPANY DURING THE PAST TWELVE MONTHS

The Directors confirm that the Company has not been involved in any fund raising activities in relation to the issuance of its equity securities within the twelve months immediately preceding the date of this announcement.

As the Placing is on a best effort basis, and the Closing is subject to the Placing Agreement not being terminated, and the satisfaction (or waiver) of a number of conditions under the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the Shares.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

"Board"	the board of Directors
"Closing"	the closing of the Placing pursuant to the terms and conditions of the Placing Agreement
"Closing Date"	22 January 2026, or at such other time and/or date as the Company and the Joint Placing Agents agree in writing and in compliance with the Listing Rules
"Company"	Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (stock code: 1501)

"connected person(s)"	has the same meaning ascribed thereto under the Listing Rules
"CSRC"	China Securities Regulatory Commission (中國證券監督管理委員會)
"CSRC Filings"	the CSRC Filing Report (including any amendments, supplements and/or modifications thereof) and any relevant supporting materials
"CSRC Filing Report"	the filing report in relation to the Placing and any transactions contemplated by the Placing Agreement to be filed with the CSRC
"Director(s)"	the director(s) of the Company
"Domestic Share(s)"	domestic ordinary share(s) with a nominal value of RMB1.00 each in the share capital of the Company
"EGM"	the 2025 first extraordinary general meeting of the Company held on 29 August 2025
"General Mandate"	the general mandate granted by a resolution passed at the EGM to the Board to allot, issue and deal with new Shares not exceeding 20% of the total number of Share in issue as at the date of passing of the resolution, that is a total of 35,200,000 Shares
"Group"	the Company and its subsidiaries
"H Share(s)"	overseas listed foreign invested ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are listed on the Main Board of the Stock Exchange
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	Hong Kong Special Administrative Region of the PRC
"Independent Third Party(ies)"	third party(ies) independent of and not connected with the Company and its connected persons and is not acting in concert (as defined in the Takeovers Code) with the Company and any of the connected persons of the Company

"Joint Placing Agents"	China International Capital Corporation Hong Kong Securities Limited and China Industrial Securities International Capital Limited
"Last Trading Day"	14 January 2026, being the date of the Placing Agreement
"Placee(s)"	any investor who is a professional, institutional, corporate or other investor and is Independent Third Party procured by the Placing Agent to subscribe for the Placing Shares pursuant to the Placing Agreement
"Placing"	the placing of the Placing Shares by or on behalf of the Joint Placing Agents on the terms and subject to the conditions set out in the Placing Agreement
"Placing Agreement"	the conditional placing agreement entered into between the Company and the Joint Placing Agents dated 14 January 2026
"Placing Price"	the price of HK$26.00 per Placing Share
"Placing Share(s)"	35,200,000 new H Shares to be allotted and issued pursuant the terms and conditions of the Placing Agreement which will rank, *pari passu*, in all respects with the Shares in issue and together with all rights attaching to as at the date of issue of the Placing Shares
"PRC"	the People's Republic of China which, for the purpose of this announcement, shall exclude Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	H Share(s) and Domestic Share(s)
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"substantial shareholder(s)"	has the same meaning ascribed thereto under the Listing Rules

"Takeovers Code"	The Codes on Takeovers and Mergers and Share Buy-back issued by the Securities and Futures Commission of Hong Kong
"trading day"	means a day on which the Stock Exchange is open for the trading of securities
"%"	per cent

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
14 January 2026

As at the date of this announcement, the Board comprises Dr. Liang Dongke and Mr. Lin Sen as executive Directors, Dr. Song Yuan, Mr. Wang Ruiqin, Ms. Chen Hongqin and Mr. Zhang Hong as non-executive Directors, and Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli as independent non-executive Directors.

* *For identification purposes only*